If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Emgality ® (galcanezumab-gnlm) injection
100 mg/mL, 120 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
EMGALITY® (galcanezumab-gnlm): Aseptic Techniques During Supply Shortages
During medical supply shortages, Lilly encourages patients to contact their health care provider for assistance.
Guidance During Medical Supply Shortages
The COVID-19 pandemic has caused widespread medical supply shortages, including alcohol swabs and bottles of 70% isopropyl alcohol.
Injection Site Preparation
As an alternative to the use of alcohol, the WHO recommends the use of soap and water for skin preparation and disinfection of injection sites.3
Enclosed Prescribing Information
3. World Health Organization. WHO best practices for injections and related procedures toolkit. Published March 2010. Accessed March 23, 2020. https://apps.who.int/iris/bitstream/handle/10665/44298/9789241599252_eng.pdf?sequence=1
COVID-19 = coronavirus disease 2019
Lilly = Eli Lilly and Company
WHO = World Health Organization
Date of Last Review: March 27, 2020